Pharmaceuticals — US PTAB Patent Cases
247 decisions indexed
Page 6 of 9 · 247 total
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s enzyme patent, arguing the claims lack adequate written description and enablement. The reply emphasizes functional language and the impossibility of testing the claimed 1,059+ PH20 variants.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck defends its PH20 enzyme patent in a PTAB Director Review proceeding, arguing that the claims satisfy §112 written description and enablement and that Halozyme's claim‑construction objections are unfounded. The petitioner also contends that Fintiv factors do not justify discretionary denial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Halozyme seeks Director Review to overturn the PTAB’s institution of a post‑grant review of its ’035 enzyme patent. The petition contends the Board mis‑interpreted claim language and mis‑applied eligibility standards, and argues that Fintiv factors demand denial of institution.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Halozyme has sought a Director Review of the PGR, and Merck has 5 business days to file a brief response without new evidence.
Biofrontera Incorporated et al. v.Sun Pharmaceutical Industries, Inc.
The USPTO denied Biofrontera's request for rehearing of the decision that refused to institute its IPR against Sun Pharmaceutical's patent 11,446,512. The Board affirmed the discretionary denial, leaving the patent unchallenged.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent 12,123,035 covering PH20 hyaluronidase mutants. The petition asserts lack of written description, lack of enablement, and obviousness of the claims. The Board has yet to decide whether to institute the trial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB instituted the PGR petition challenging Halozyme's patent covering modified PH20 polypeptides. The Board found that the claims were not sufficiently supported by the specification regarding enablement and obviousness, despite Petitioner's arguments about the genus size.
Ajinomoto Co., Inc. v.AbTis Co., Ltd.
Ajinomoto has filed an IPR petition challenging AbTis’s U.S. Patent 11,896,675 covering site‑specific antibody‑drug conjugates. The petitioner alleges lack of written description, improper priority, and that all 13 claims are anticipated or obvious over several pre‑grant publications and conference disclosures. The petition seeks cancellation of every claim.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE challenged The Johns Hopkins University's claims regarding FAP-α targeting moieties based on obviousness and patentability issues (103/112). The Board instituted the PGR, finding that the claims face significant challenges related to enablement and indefiniteness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Halozyme has filed a Director Review request asking the PTAB to overturn its institution of a post‑grant review of the ’600 hyaluronidase protein patent, arguing procedural errors and an improper claim construction.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC filed a response defending the institution of a post‑grant review of Halozyme’s enzyme patent. The brief rebuts Halozyme’s eligibility, claim‑construction, and Fintiv arguments, emphasizing that the Board’s earlier findings remain sound.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck files a PGR petition challenging Halozyme’s protein‑based contraceptive patent, arguing the claims lack written description and enablement. The reply emphasizes that the specification does not support the broad genus of modified PH20 polypeptides claimed.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The USPTO Director denied Merck’s request for a review of the PTAB’s institution decisions in four Halozyme patent cases, leaving the institution findings intact.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on modified PH20 polypeptides in a PGR proceeding. The Board found likelihood of prevailing based on arguments regarding the genus's scope and potential lack of enablement/obviousness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Halozyme seeks Director Review to overturn the PTAB’s institution of a post‑grant review against its hyaluronidase patent, arguing filing‑date errors, improper claim construction, and Fintiv factors favoring denial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed a petition to invalidate Halozyme’s ’298 patent covering modified PH20 polypeptides, arguing the claims lack written description and enablement. The reply attacks Halozyme’s reliance on functional language and disclaimed dependent claims.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s request for Director review after the PTAB instituted a post‑grant review of U.S. Patent 12,018,298 covering modified PH20 polypeptides. Merck argues the eligibility and claim‑construction issues are meritless and that the Fintiv factors favor institution.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck challenges Halozyme’s broad PH20 hyaluronidase patent, asserting lack of written description, enablement, and obviousness of the claimed protein variants.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
Samsung Bioepis has filed an IPR petition challenging 48 claims of Regeneron’s anti‑VEGF ophthalmic formulation patent, arguing the claims are obvious over prior‑art formulations and presentation data.
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
Samsung Bioepis sought to invalidate numerous claims of Regeneron Pharmaceuticals' ophthalmic formulations using grounds of obviousness (103). The PTAB denied institution based on a holistic Fintiv analysis, citing significant overlap with ongoing district court and MDL proceedings.
Azurity Pharmaceuticals, Inc. v.EXELIXIS, INC.
Azurity Pharmaceuticals has filed an IPR petition seeking cancellation of claims 1‑3 of Exelixis’s U.S. Pat. 11,298,349 covering oral cabozantinib (L)-malate formulations. The petition alleges anticipation by the earlier Wilson patent and obviousness over Brown, Kubo and Remington, while arguing that discretionary denial factors do not apply.
Azurity Pharmaceuticals, Inc. v.EXELIXIS, INC.
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Helena Laboratories Corporation v.Sebia
Helena Laboratories Corporation's IPR challenge against Sebia regarding hemoglobin analysis claims was denied by the PTAB. The Board found that the petitioner failed to demonstrate material error in the Examiner's rejection, particularly concerning prior art references like Shihabi and Huang.
Cipla Limited v.Gilead Sciences, Inc.
Cipla has filed an IPR petition challenging Gilead’s 2023 ‘802 patent covering a bictegravir/TAF/FTC single‑tablet HIV regimen, asserting obviousness over multiple prior‑art references.
Cipla Limited v.Gilead Sciences, Inc.
The PTAB denied Cipla Limited's IPR petition against Gilead Sciences regarding patent 11,744,802, citing the advanced stage of parallel district court litigation and lack of compelling merits.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma has filed an IPR petition seeking cancellation of all 30 claims of Ellodi's 11,260,061 patent covering orally disintegrating corticosteroid tablets. The petition relies on Perrett, Dohil2009, and Venkatesh as prior art to argue obviousness under §103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.